Investment Rating - The report maintains a "Buy" rating for Weigao Orthopedics [3][6]. Core Views - The company's performance is expected to recover significantly in 2024, with revenue and net profit showing comprehensive growth, reversing the downward trend observed since 2022 [1][3]. - The core product lines are anticipated to see both volume and price increases, with further recovery expected in 2025 [2][3]. - Weigao Orthopedics is actively diversifying its research and development efforts, expanding into areas outside of centralized procurement [2][3]. Financial Forecast - The company is projected to achieve revenues of 15.75 billion, 18.21 billion, and 21.10 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 2.65 billion, 3.17 billion, and 3.61 billion yuan [3][5]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 0.66, 0.79, and 0.90 yuan, with price-to-earnings (PE) ratios of 39.30, 32.83, and 28.79 respectively [3][5]. Business Overview - Weigao Orthopedics is recognized as a leading domestic orthopedic consumables company, with a comprehensive product line covering joints, spine, trauma, and sports medicine [10][11]. - The company has seen a significant increase in sales volume across its three main product lines in 2024, marking a turnaround in performance [22][25]. - The company’s revenue structure is healthy, with contributions from joint and spine products being nearly equal, and low dependency on any single business line [19][20]. Market Dynamics - The risk of significant price reductions due to centralized procurement has been alleviated, with stable pricing expected in 2025 [31][33]. - The aging population is driving demand for orthopedic products, with a notable increase in the prevalence of conditions such as osteoarthritis and osteoporosis among older adults [35][37]. - The market for orthopedic consumables is expected to grow as the number of elderly patients increases, leading to higher clinical demand for orthopedic surgeries [44][45]. Competitive Position - Weigao Orthopedics has maintained a strong market share in the orthopedic consumables sector, particularly in the artificial joint segment, where it has benefited from the national procurement policies [45][51]. - The company’s pricing strategy and product quality have positioned it favorably against both domestic and international competitors [64][65].

Investment Rating - The industry investment rating is maintained at "Overweight" [3][58] Core Views - The lithium battery materials industry experienced a slight decline of 0.26% last week, underperforming the benchmark (CSI 300) by 1.37 percentage points [4][10] - The industry valuation (TTM P/E) decreased by 0.08x to 32.12x, currently at 21.9% of the long-term historical percentile [4][10] - The overall market dynamics indicate that while downstream demand remains high due to promotional policies, the growth rate of energy storage demand is slowing, leading to overcapacity and high inventory levels across most industry segments [7][58] Summary by Sections Market Performance - The lithium battery materials industry saw a relative return of -4% over the past three months and a 0% return over the past twelve months [4] - The industry valuation has returned to a lower historical level, indicating limited room for valuation recovery unless there is an improvement in marginal profitability [9][58] Raw Material Prices - Lithium source prices continued to decline, with carbonate lithium spot and futures prices dropping by 0.78% and 1.94% respectively [8][14] - The prices of ternary precursor materials remained stable, while the prices of phosphoric iron lithium continued to weaken, with a week-on-week drop of 0.6% [6][28] Supply and Demand Dynamics - The demand for phosphoric iron lithium is slowing, with production expected to decrease, although profits have slightly improved but remain negative [28] - The overall operating rate in the industry is high at 81.79%, but there is a continuous accumulation of inventory due to oversupply [7][53] Investment Recommendations - The report suggests that the current industry valuation is at a historical low, and the potential for valuation recovery depends on the improvement of industry profitability [9][58] - The recommendation to maintain an "Overweight" rating reflects the expectation of future demand recovery and potential profitability improvements [58]

Investment Rating - The report maintains an "Overweight" rating for the automotive industry [2][7]. Core Insights - The new mandatory installation of AEBS (Automatic Emergency Braking System) is expected to drive the development of the related industrial chain [4][6]. - The implementation of the new standard will enhance R&D efforts among automotive companies, leading to increased resource allocation for innovation and improvement, thus fostering collaborative growth across the supply chain [6][7]. - The market penetration of AEBS is projected to rise significantly, benefiting component suppliers in the short term, while automotive electronics and smart driving system integrators will gain from market expansion in the medium term [7][23]. Summary by Sections Industry Performance - Over the past week (May 12 - May 16), the automotive industry index rose by 2.40%, outperforming the CSI 300 index by 1.29 percentage points [9]. - Since the beginning of 2025, the automotive industry index has increased by 11.83%, again surpassing the CSI 300 index by 13.0 percentage points [9]. Market Trends - The overall installation rate of AEBS in passenger vehicles was 56.5% in early 2025, showing a year-on-year increase of 3.3 percentage points [5]. - High-end models priced above 320,000 yuan have an installation rate exceeding 93%, while entry-level models priced below 80,000 yuan have a much lower rate of 2.6% [5]. Investment Recommendations - The report suggests that the automotive industry will benefit from the new regulations, with short-term gains for AEBS component suppliers, medium-term benefits for automotive electronics and smart driving system integrators, and long-term advantages for autonomous driving technology providers and vehicle manufacturers [7][23].

Investment Rating - The report assigns an "Accumulate" rating to the company, indicating a positive outlook for future performance [52]. Core Insights - The company leverages its first-mover advantage and cost-effectiveness to maintain a leading position in the Wi-Fi MCU market, with a market share of 27.0% in 2022 [11][44]. - The integration of hardware and software, along with a robust developer ecosystem, creates a strong competitive moat for the company [4][28]. - The company is expanding its product matrix by focusing on "processing + connectivity," which includes new high-performance processors and AI capabilities [4][20]. - The company is responding to the AIoT trend by upgrading its chip technology, including the development of RISC-V based AI chips to enhance processing capabilities [4][38]. Summary by Sections First-Mover Advantage and Cost-Effectiveness - The company has established a leading position in the Wi-Fi MCU market due to its first-mover advantage and competitive pricing, particularly in smart home and consumer electronics sectors [4][11]. - The smart home business is expected to grow at approximately 30%, while non-smart home sectors are anticipated to grow even faster [11]. Expanding Product Matrix - The company has been diversifying its product offerings since its inception in 2008, moving from Wi-Fi MCUs to include high-performance processors and AI capabilities [4][20]. - Recent product launches, such as the P4, signify the company's entry into higher-performance processing markets [4][27]. Hardware-Software Integration and Developer Ecosystem - The company has developed the ESP-IDF operating system, which facilitates easy integration for users and reduces development costs [4][28]. - The ESP RainMaker platform allows users to quickly build IoT devices without managing infrastructure, enhancing user experience [31][32]. AIoT Trend and Chip Technology Upgrades - The company is focusing on developing AI chips based on RISC-V architecture to meet increasing demands for AI processing in IoT devices [4][38]. - The planned investments in AI chip development are expected to enhance the company's market position and product offerings [42]. Profit Forecast and Valuation - The company is projected to achieve revenues of 2.705 billion, 3.379 billion, and 4.221 billion yuan from 2025 to 2027, with corresponding growth rates of 34.8%, 24.9%, and 24.9% [44]. - The expected net profits for the same period are 426 million, 579 million, and 699 million yuan, with growth rates of 25.5%, 35.9%, and 20.8% [44].

Investment Rating - The industry investment rating is maintained as "Buy" [1] Core Views - The FGF21 target in the MASH field has achieved significant breakthroughs, enhancing its value and suggesting potential investment opportunities in domestic pipelines [4][5] - The domestic innovative drug industry is expected to enter a turning point in 2025, shifting from capital-driven to profit-driven trends, with opportunities for both performance and valuation recovery [6][19] Summary by Sections Industry Performance - Over the past 12 months, the A-share biotechnology sector has shown a relative performance of -1.3% compared to the CSI 300, with an absolute return of 10.9% [2][3] Clinical Progress and Breakthroughs - Akero's drug Efruxifermin has shown a 39% improvement in liver fibrosis in MASH patients after 96 weeks of treatment, compared to 15% in the placebo group [4][11] - The drug efimosfermin alfa demonstrated a 68% improvement in liver fibrosis in moderate to advanced MASH patients after 24 weeks, significantly outperforming the control group [12][15] Investment Recommendations - The report recommends focusing on two main investment lines: 1. Pharma companies transitioning to innovation, such as Huadong Medicine and Aosaikang, which are expected to see performance and valuation increases [19] 2. Biotech companies with potential for overseas product registrations [19] Supportive Policies - The introduction of the first Class B medical insurance directory is expected to expand the market for innovative drugs, alongside ongoing support policies for the entire industry chain [18][19]

证券研究报告 （增持，维持） 对《持续稳定和活跃资本市场》的相关政策解读 及券商板块展望 分析师：张智珑 证书编号：S0500521120002 2025年05月15日 目 录 一、《持续稳定和活跃资本市场》相关政策解读 二、证券行业2025Q1业绩综述及展望 三、投资建议及风险提示 2 一 、《持续稳定和活跃资本市场》相关政策解读 3 高层再次重申"持续稳定和活跃资本市场" ，有力提振市场情绪 ◼ 5月14日上午，证监会公众号转载了经济日报发表的《持续稳定和活跃资本市场》文章，对4月政治局会议 提出的"持续稳定和活跃资本市场"进行了更深入的解读，向市场传递积极信号，非银板块大幅上涨，提 振了市场情绪。 | 时间 | 会议或文章 | | 资本市场相关表述及政策 | | --- | --- | --- | --- | | 4月25日 | 中央政治局会议 | | 提出"持续稳定和活跃资本市场" | | 5月7日 | 国新办发布会 | • • | 证监会提出三方面举措： | | | | • | 全力巩固市场回稳向好势头。全力支持中央汇金公司发挥好类"平准基金"作用。 | | | | | 突出服务新质生产力发展这个重 ...

证券研究报告 2025 年 05 月 13 日 湘财证券研究所 行业研究 医疗服务事件点评 关税缓和双机遇：CXO 估值修复与医疗器械全球突围 事件： 2025 年 05 月 12 日，商务部公布了中美日内瓦经贸会谈联合声明。声明指 出：中美双方近期会将 4 月 2 日相关的 34%关税分为 24%（暂缓 90 天） 和 10%，中国还将暂停或取消自 2025 年 4 月 2 日起针对美国的非关税反 制措施。中美双方未来还会建立机制，继续就经贸关系进行协商。 核心要点： CXO 受中美关税影响较为复杂，政策边际缓和有望迎来估值修复 中美关税边际缓和有利于医疗设备降低生产成本，扩大海外市场份额 近年来国内企业在高端设备、介入治疗、诊断试剂等领域不断突破，逐步 替代进口产品。然而，由于部分关键零部件、检测设备仍依赖进口，关税 波动曾对企业的成本结构和利润空间构成压力。此次中美关税缓和，有助 于稳定供应链成本，提升企业在全球市场的竞争力，尤其是在美国 FDA、 欧盟 CE 等认证体系下的产品推广和市场渗透。 此外，中美关税缓和有利于直接销往美国的医疗器械企业的业务开拓：（1） 价格敏感市场机会增加：美国基层医疗市场 ...

Core Insights - The recent US-China trade conflict has seen a temporary easing, with significant tariff reductions benefiting key export industries [4][5] - The US has reduced tariffs on Chinese goods, with the effective rate dropping to approximately 44.60%, which is a substantial decrease from previous levels [4][6] - The impact of these tariffs on China's GDP is estimated to be around 0.8%, with a projected decline in net exports to the US of approximately $54 billion [4][8] Industry Analysis - Key export sectors that will benefit from the tariff reductions include machinery products (49.08%), mineral chemical products (26.24%), furniture products (11.16%), and steel products (5.77%) [6] - The reduction in tariffs is expected to lead to a recovery in export expectations for these industries, which were previously affected by the "reciprocal tariffs" [6][9] - On the import side, China will also lower tariffs on US goods, leading to an anticipated increase in imports of machinery electronics, agricultural products, energy, and chemicals [6] Future Outlook - Tariffs will remain a focal point for future economic developments, with the 24% tariff being temporarily suspended for 90 days, allowing for further negotiations [8] - The export growth rate for China is expected to remain high, with the effects of tariffs likely to manifest in the economic data for May and June [8] - The A-share market is projected to continue a "slow bull" trend in 2025, with investment opportunities in technology, green sectors, consumption, and infrastructure [9]

证券研究报告 2025 年 04 月 29 日 湘财证券研究所 公司研究 康华生物（300841.SZ）业绩点评 狂苗销量阶段性下降，渠道拓展稳步推进 相关研究： 1. 《狂苗领域技术及临床先发 优势明显，诺如疫苗带来业绩新 增长极》 20241203 公司评级：买入（维持） 近十二个月公司表现 % 1 个月 3 个月 12 个月 相对收益 11 -7 -18 绝对收益 13 1 -29 核心要点： ❑ 公允价值变动影响 2024Q4 利润端，高基数及费用率上升影响 2025Q1 业绩 根据公司 2024 年年报及 2025 年一季报，2024Q4 公司实现营业收入 3.71 亿元，受参股公司确认公允价值变动损失影响（合计-5868.82 万元），归母 净利润为-725 万元，扣非归母净利润 4492.55 万元。2024Q1 公司营收 3.11 亿元，其中包括重组六价诺如病毒疫苗海外授权首付款 1.06 亿元，剔除上 年同期首付款后，2025Q1 营收同比下降 32.75%，扣非归母净利润同比下 降 65.5%。 2024 年受研发项目阶段性投入减少，研发费用率为 9.22%，同比下降 6.82pct；受市 ...

Macro Strategy and North Exchange - The macro policy remains stable with LPR unchanged at 3.10% for 1-year and 3.60% for 5-year [5] - Industrial enterprise profits showed a year-on-year increase of 2.60% in March, marking the first positive growth since the previous year [5] - The Central Political Bureau emphasized the need for high-quality development to address international economic and trade struggles, focusing on "Four Stabilities" [7][8] - The government plans to accelerate the issuance of special bonds and long-term bonds, with a deficit rate set at around 4% and a total deficit scale of 5.66 trillion yuan, an increase of 1.6 trillion yuan from 2024 [8] - Monetary policy will include timely reductions in reserve requirements and interest rates, along with new structural monetary policy tools to support innovation and consumption [10][11] A-Share Market Overview - From April 21 to April 27, 2025, most A-share indices rose, with the Shanghai Composite Index increasing by 0.56% and the Shenzhen Component Index by 1.38% [15] - The market is expected to maintain a narrow fluctuation state due to the recent "reciprocal tariffs" imposed by the US and the upcoming May Day holiday [15][23] - The report indicates a "slow bull" market trend for A-shares in 2025, with a focus on technology, green energy, consumption, and infrastructure sectors [23] North Exchange Market Overview - As of April 25, 2025, the North Exchange had 265 listed stocks, with an average total market value of 755.47 billion yuan, an increase of 1.53% from the previous week [24] - The liquidity in the North Exchange decreased, with average trading volume dropping by 9.79% to 1.384 billion shares [25] - The North Exchange's 50 Index closed at 1300.19 points, down 2.16% from the previous week [26] Industry Insights: Food and Beverage - Salted Fish reported a revenue of 5.304 billion yuan and a net profit of 640 million yuan for 2024, reflecting a year-on-year increase of 28.89% and 26.53% respectively [34] - The company is focusing on core product categories with strong growth, particularly in spicy snacks and baked goods, with significant revenue increases [35] - Salted Fish is accelerating its overseas expansion, with a projected revenue of 6.678 billion yuan in 2025, growing at 25.9% year-on-year [38] Industry Insights: Medical Devices - The sales of ultrasound imaging devices showed a significant recovery in Q1 2025, with sales revenue increasing by 87.95% year-on-year [40] - The report highlights a shift towards domestic brands, with domestic sales accounting for 37.79% of the market share in 2024, up from 34.20% in 2023 [42] - The report suggests a positive outlook for domestic ultrasound device manufacturers like Mindray and KAILI Medical, as the market for these devices is expected to continue recovering [48]